Anticoagulation options for intermittent haemodialysis

Area of Science:

• Nephrology
• Hematology
• Biomaterials Science

Background:

• Extracorporeal circuit anticoagulation was a significant hurdle in developing chronic intermittent hemodialysis.
• Coagulation initiation in hemodialysis circuits stems from bioincompatibility, activating leukocytes, platelets, and coagulation cascades.
• This activation is triggered by dialyzer surfaces and tubing, initiating the contact coagulation cascade.

Purpose of the Study:

• To review the current landscape of anticoagulation strategies in hemodialysis.
• To compare the advantages and disadvantages of different anticoagulant classes.
• To highlight emerging challenges such as heparin-induced thrombocytopenia.

Main Methods:

• Literature review of anticoagulation practices in hemodialysis.
• Comparative analysis of unfractionated heparin, low molecular weight heparin, and regional anticoagulants.
• Discussion of the mechanisms of bioincompatibility and coagulation activation.
• Examination of the incidence and management of heparin-induced thrombocytopenia.

Main Results:

• Unfractionated heparin is widely used but associated with less predictable pharmacokinetics.
• Low molecular weight heparin offers improved pharmacokinetics, reduced dialyzer fouling, and fewer adverse effects like osteoporosis.
• Regional anticoagulants reduce hemorrhage risk but can be costly or complex (e.g., citrate).
• Immune-mediated heparin-induced thrombocytopenia is an increasing concern, requiring direct thrombin inhibitors or heparinoids.

Conclusions:

• Low molecular weight heparin presents a favorable alternative to unfractionated heparin in hemodialysis.
• The choice of anticoagulant must balance efficacy, safety, cost, and patient-specific risks.
• Emerging anticoagulation challenges necessitate careful patient monitoring and alternative therapeutic strategies.